Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JANET L DITTUS

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecology

NPI
1104817667
CMS profile
321812
Location
NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$58.91

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Gift $35.20 1
Food and Beverage $23.71 2

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
ASCEND THERAPEUTICS US, LLC $35.20 1
PFIZER INC. $23.71 2

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JANET L DITTUS

NPI 1104817667 · CMS profile ID 321812

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecology

NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104817667?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JANET L DITTUS, NPI 1104817667, CMS profile ID 321812. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104817667?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JANET L DITTUS, NPI 1104817667, CMS profile ID 321812. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104817667?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JANET L DITTUS, NPI 1104817667, CMS profile ID 321812, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1104817667?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $58.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $11.5804/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743176389 CMS
ASCEND THERAPEUTICS US, LLC $35.2002/13/2020 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742114409 CMS
PFIZER INC. $12.1301/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743158617 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $239.38 16
PY2020 $58.91 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020
Generated from
OP_DTL_GNRL_PGYR2020_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $76,960.26 59
PY2024 Principal investigator $125,208.78 84
PY2023 Principal investigator $164,586.56 110
PY2022 Principal investigator $206,862.26 97
PY2021 Principal investigator $276,121.42 137
PY2020 Principal investigator $399,361.17 89
PY2019 Principal investigator $337,852.09 56

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

110 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $176.66 12/31/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998414407
Principal investigator 1 ABBVIE INC. $2,406.88 12/28/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998412957
Principal investigator 1 ABBVIE INC. $3,575.63 12/28/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998412959
Principal investigator 1 ABBVIE INC. $24.34 12/19/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998412319
Principal investigator 1 ABBVIE INC. $17,721.26 12/13/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998411599
Principal investigator 1 ABBVIE INC. $401.25 12/07/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 998410953
Principal investigator 1 ABBVIE INC. $60.84 12/05/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998410555
Principal investigator 1 ABBVIE INC. $3,575.63 12/04/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998409721
Principal investigator 1 ABBVIE INC. $100.00 11/30/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998409225
Principal investigator 1 ABBVIE INC. $2,406.88 11/30/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998409287
Principal investigator 1 ABBVIE INC. $46.73 11/29/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998409155
Principal investigator 1 ABBVIE INC. $77.89 11/21/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998408599
Principal investigator 1 ABBVIE INC. $35.20 11/16/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998408369
Principal investigator 1 ABBVIE INC. $315.00 11/14/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998407991
Principal investigator 1 ABBVIE INC. $17.25 11/09/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998407867
Principal investigator 1 ABBVIE INC. $116.74 11/02/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998405661
Principal investigator 1 ABBVIE INC. $100.00 11/02/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998405733
Principal investigator 1 ABBVIE INC. $2,406.88 11/02/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998405735
Principal investigator 1 ABBVIE INC. $527.50 10/25/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998404803
Principal investigator 1 ABBVIE INC. $297.50 10/25/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998404815
Principal investigator 1 ABBVIE INC. $46.70 10/25/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998404845
Principal investigator 1 ABBVIE INC. $90.00 10/19/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998404543
Principal investigator 1 ABBVIE INC. $90.00 10/19/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998404629
Principal investigator 1 ABBVIE INC. $8.80 10/17/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998404337
Principal investigator 1 ABBVIE INC. $38.91 10/12/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998404127
Principal investigator 1 ABBVIE INC. $1,586.25 10/05/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998402553
Principal investigator 1 ABBVIE INC. $3,575.63 10/04/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998401731
Principal investigator 1 ABBVIE INC. $118.60 10/04/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998401733
Principal investigator 1 ABBVIE INC. $2,406.88 09/27/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998401239
Principal investigator 1 ABBVIE INC. $2,406.88 09/27/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998401241
Principal investigator 1 ABBVIE INC. $59.30 09/26/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998401097
Principal investigator 1 ABBVIE INC. $2,406.88 09/21/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998400375
Principal investigator 1 ABBVIE INC. $2,406.88 09/21/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998400377
Principal investigator 1 ABBVIE INC. $20.10 09/21/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998400389
Principal investigator 1 ABBVIE INC. $2,856.25 09/07/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998398747
Principal investigator 1 ABBVIE INC. $58.27 09/06/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998398421
Principal investigator 1 ABBVIE INC. $1,322.50 08/31/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 998397395
Principal investigator 1 ABBVIE INC. $100.00 08/31/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998397529
Principal investigator 1 ABBVIE INC. $580.00 08/30/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998397337
Principal investigator 1 ABBVIE INC. $29.12 08/24/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998396647
Principal investigator 1 ABBVIE INC. $37.96 08/23/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998396465
Principal investigator 1 ABBVIE INC. $315.00 08/17/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998395761
Principal investigator 1 ABBVIE INC. $936.25 08/17/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998395763
Principal investigator 1 ABBVIE INC. $2,406.88 08/17/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998395765
Principal investigator 1 ABBVIE INC. $116.48 08/17/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998395767
Principal investigator 1 ABBVIE INC. $3,575.63 08/16/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998395643
Principal investigator 1 ABBVIE INC. $100.00 08/15/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998395173
Principal investigator 1 ABBVIE INC. $572.50 08/15/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998395175
Principal investigator 1 ABBVIE INC. $99.20 08/09/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998393501
Principal investigator 1 ABBVIE INC. $3,026.25 08/09/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998393503
Principal investigator 1 ABBVIE INC. $49.60 07/27/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998392611
Principal investigator 1 ABBVIE INC. $19.53 07/27/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998392615
Principal investigator 1 ABBVIE INC. $2,406.88 07/20/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998391999
Principal investigator 1 ABBVIE INC. $2,406.88 07/20/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998392001
Principal investigator 1 ABBVIE INC. $2,223.75 07/06/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998389505
Principal investigator 1 ABBVIE INC. $100.00 07/06/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998389507
Principal investigator 1 ABBVIE INC. $6,836.88 06/13/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998386817
Principal investigator 1 ABBVIE INC. $59.57 06/09/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998386627
Principal investigator 1 ABBVIE INC. $99.29 06/09/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998386629
Principal investigator 1 ABBVIE INC. $580.00 06/09/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998386631
Principal investigator 1 ABBVIE INC. $45.00 06/08/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998386153
Principal investigator 1 ABBVIE INC. $19.58 06/08/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998386255
Principal investigator 1 ABBVIE INC. $99.29 06/07/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998385567
Principal investigator 1 ABBVIE INC. $100.00 06/06/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 998385339
Principal investigator 1 ABBVIE INC. $99.29 06/01/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998385185
Principal investigator 1 ABBVIE INC. $3,575.63 05/25/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998384529
Principal investigator 1 ABBVIE INC. $3,575.63 05/25/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998384531
Principal investigator 1 ABBVIE INC. $2,406.88 05/25/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998384533
Principal investigator 1 ABBVIE INC. $481.38 05/25/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998384559
Principal investigator 1 ABBVIE INC. $936.25 05/25/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998384561
Principal investigator 1 ABBVIE INC. $20.05 05/24/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998384351
Principal investigator 1 ABBVIE INC. $99.33 05/24/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998384363
Principal investigator 1 ABBVIE INC. $1,702.50 05/18/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998384007
Principal investigator 1 ABBVIE INC. $2,406.88 05/17/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998383857
Principal investigator 1 ABBVIE INC. $1,925.50 05/17/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998383871
Principal investigator 1 ABBVIE INC. $100.00 05/17/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998383873
Principal investigator 1 ABBVIE INC. $2,401.25 05/11/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998382635
Principal investigator 1 ABBVIE INC. $99.42 05/04/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998380713
Principal investigator 1 ABBVIE INC. $90.00 05/04/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998380715
Principal investigator 1 ABBVIE INC. $156.25 05/04/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 998380717
Principal investigator 1 ABBVIE INC. $3,575.63 04/24/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998379367
Principal investigator 1 ABBVIE INC. $74.86 04/13/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998378419
Principal investigator 1 ABBVIE INC. $3,575.63 04/13/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998378421
Principal investigator 1 ABBVIE INC. $24.86 04/13/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998378505
Principal investigator 1 ABBVIE INC. $1,502.50 04/13/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998378535
Principal investigator 1 ABBVIE INC. $3,508.75 04/11/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 998377561
Principal investigator 1 ABBVIE INC. $99.42 04/06/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998377359
Principal investigator 1 ABBVIE INC. $100.00 04/06/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998377415
Principal investigator 1 ABBVIE INC. $101.07 04/06/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998377417
Principal investigator 1 ABBVIE INC. $477.50 04/06/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998377419
Principal investigator 1 ABBVIE INC. $33.17 03/30/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998376107
Principal investigator 1 ABBVIE INC. $49.75 03/23/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998375591
Principal investigator 1 ABBVIE INC. $3,575.63 03/16/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998374353
Principal investigator 1 ABBVIE INC. $2,406.88 03/16/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998374373
Principal investigator 1 ABBVIE INC. $100.00 03/16/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998374375
Principal investigator 1 ABBVIE INC. $936.25 03/16/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998374621
Principal investigator 1 ABBVIE INC. $2,406.88 03/16/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998374645
Principal investigator 1 ABBVIE INC. $8,000.00 03/07/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 998372545
Principal investigator 1 ABBVIE INC. $12,050.63 03/02/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998372207
Principal investigator 1 ABBVIE INC. $67.28 02/22/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998371635
Principal investigator 1 ABBVIE INC. $100.00 02/16/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998371157
Principal investigator 1 ABBVIE INC. $3,050.00 02/16/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998371303
Principal investigator 1 ABBVIE INC. $100.00 02/09/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998369653
Principal investigator 1 ABBVIE INC. $135.00 02/02/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 998368607
Principal investigator 1 ABBVIE INC. $13.75 02/02/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 998368609
Principal investigator 1 ABBVIE INC. $9,906.90 01/12/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 998366323
Principal investigator 1 ABBVIE INC. $99.81 01/12/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998366385
Principal investigator 1 ABBVIE INC. $135.00 01/06/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 998364431
Principal investigator 1 ABBVIE INC. $66.51 01/06/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 998364433
Principal investigator 1 ABBVIE INC. $7,406.25 01/04/2023 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 998363827